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Background: Pericyte loss is a cardinal feature of early diabetic retinopathy. We previously reported that highly oxidized-
glycated low density lipoprotein (HOG-LDL) induces pericyte apoptosis in vitro. In this study, we investigated the role
of the mitogen-activated protein kinase (MAPK) signaling pathways in HOG-LDL-induced apoptosis in human pericytes.
Methods: Human retinal capillary pericytes (HRCP) were exposed to native LDL (N-LDL) and HOG-LDL, and apoptosis
was measured using flow cytometry. Time- and dose-dependent responses of extracellular signal-regulated kinase (ERK),
p38, and Jun N-terminal kinase (JNK) following exposure to N-LDL or HOG-LDL were determined using western
blotting. U0126 (ERK inhibitor), SB203580 (p38 inhibitor), and SP600125 (JNK inhibitor) were used to determine the
role of MAPK signaling in HOG-LDL-induced apoptosis.
Results: HOG-LDL induced apoptosis in HRCP in a dose-dependent manner at concentrations from 5 to 50 mg/l, with a
constant effect from 50 to 200 mg/l. When compared to serum-free medium (SFM), this effect of HOG-LDL was found
to be significant at all doses above 10 mg/l. In contrast, N-LDL at 200 mg/l did not induce apoptosis compared with SFM.
Exposure to N-LDL versus HOG-LDL induced similar phosphorylation of ERK, p38, and JNK, peaking at 5 min, with
similar dose-dependent responses up to 25 mg/l that were constant from 25 to 100 mg/l. Blocking of the ERK, p38, and
JNK pathways did not inhibit pericyte apoptosis induced by HOG-LDL.
Conclusions: Our data suggest that apoptosis induced by HOG-LDL in HRCP is independent of the activation of MAPK
signaling pathways.
Diabetic  retinopathy  (DR)  is  a  leading  cause  of  the
blindness in the working age (18–65 years old) population
[1,2]. An important characteristic of its early stages is pericyte
loss [3], which is associated with increased pericyte apoptosis
[2,4,5]. Retinal capillary pericytes mediate vascular stability
and control endothelial cell proliferation. Loss of pericytes
results in endothelial cell proliferation and enhances abnormal
angiogenesis in the retina [5]. Although the pathogenesis of
pericyte loss is not clear, poor glycemic control, hypertension,
dyslipidemia (especially modified low-density lipoproteins),
and  duration  of  diabetes  are  all  implicated  [6-9].  It  is
hypothesized that retinal capillary leakage during the early
stage of DR [10] enables LDL to be extravasated and trapped
in  the  extravascular  and  subendothelial  spaces,  and  that
subsequent  glycation  and  oxidation  of  extravasated  LDL
under hyperglycemia and enhanced oxidative stress lead to
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retinal vascular injury [11-13]. These notions are supported
by  our  previous  studies,  which  showed  highly  oxidized-
glycated low density lipoprotein (HOG-LDL) significantly
induced  apoptosis  in  cultured  bovine  retinal  capillary
endothelial cells and pericytes, and in human retinal capillary
pericytes (HRCP) [14-16], and induced many alterations in
gene expression and function in HRCP [17,18]. Further, our
recent  immunohistochemical  studies  have  shown  that
oxidized  LDL  is  absent  in  healthy  retinas,  but  present  in
diabetic retinas to an extent proportional to the severity of DR
[16]. The underlying mechanisms by which HOG-LDL may
trigger pericyte loss include induction of DNA fragmentation,
activation  of  caspase  pathways,  and  mitochondrial
dysfunction [15,16].
The mitogen-activated protein kinase (MAPK) signaling
pathways  are  activated  by  different  extracellular  stimuli,
resulting  in  a  wide  range  of  cellular  responses,  including
apoptosis, proliferation, and inflammation. In mammals, three
major MAPK pathways have been identified: extracellular
signal-regulated  kinases  (ERK),  p38,  and  stress  activated
protein  kinases  (SAPK)/c-Jun-N-terminal  kinase  (JNK).
Accumulating  studies  show  that  MAPK  pathways  are
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135associated  with  apoptosis  triggered  by  oxidized  LDL  in
vascular  cells  [19-21].  With  regard  to  pericyte  loss,
phosphorylation of p38 MAPK is involved in retinal capillary
pericyte  loss  induced  by  modification  of  fibronectin  with
alpha-dicarbonyl compounds [22]. Therefore, the possibility
that MAPK signaling pathways might be involved in pericyte
loss induced by modified LDL merits investigation.
In  the  present  study,  we  investigated  whether  the
apoptotic effects of HOG-LDL versus native LDL (N-LDL)
on HRCP are associated with alterations in the activation of
MAPK signaling pathways. We tested the involvement of the
three known series of MAPK cascades: ERK1/2, p38, and
JNK.  The  results  showed  that  N-LDL  and  HOG-LDL
activated all three MAPK signals, but to a similar extent, and
that inhibition of the ERK, p38, and JNK pathways did not
affect  the  amount  of  apoptosis  induced  by  HOG-LDL.
Therefore, we conclude that apoptosis induced by exposure to
HOG-LDL in HRCP is independent of activation of MAPK
pathways.
METHODS
This study was approved by the Institutional Review Boards
at  the  University  of  Oklahoma  Health  Sciences  Center
(Oklahoma City, OK) and the Medical University of South
Carolina (Charleston, SC). It was conducted according to
Declaration  of  Helsinki  principles,  with  written  informed
consent obtained from all study participants
Cell  culture:  HRCP  were  obtained  from  Cambrex
(Walkersville, MD). These cells were cultured with EBM-2
basal  serum-free  culture  medium  (SFM)  and  EGM-2-MV
SingleQuots  growth  supplement,  which  contained  the
following  ingredients  obtained  from  Clonetics®
(Walkersville, MD): 5% fetal bovine serum, 0.1% hEGF,
0.04% hydrocortisone, 0.1% VEGF, 0.4% hFGF-B, 0.1% R3-
IGF-1, 0.1% ascorbic acid, and 0.1% GA-1000. HRCP from
passages 4–10 were used.
LDL  isolation  and  modification:  Protocols  employed
were as previously reported [17,23]. Briefly, human LDL was
isolated by sequential ultracentrifugation (d=1.019–1.063) of
pooled plasma. The pooled plasma was obtained on seven
occasions, and was provided on each occasion by 4–6 fasting
normal  healthy  volunteer  subjects  who  were  recruited  by
advertising. Different groups of volunteer subjects were used
on  each  occasion  to  ensure  that  results  that  could  be
generalized. Volunteers, 71% of whom were male, were aged
20  to  40  years,  and  were  taking  neither  prescription
medications nor antioxidant vitamins. Each volunteer was
documented as being non-diabetic (normal HBA1c, fasting
glucose), having normal renal function (blood urea nitrogen,
serum creatinine), and normal serum lipid profiles. N-LDL
and glycated LDL (G-LDL) were prepared by incubating LDL
with and without freshly prepared 50 mM glucose for 72 h at
37  °C  under  anti-oxidant  conditions  (1  mM  N,N-bis[2-
(bis[carboxymethyl]-amino)ethyl]glycine  (DTPA)  and
270 μM EDTA, with sustained nitrogen gas). HOG-LDL was
prepared from G-LDL by oxidizing in the presence of 10 μM
CuCl2 (24 h, 37 °C), followed by dialysis at 4 °C for 24 h.
Protein in LDL preparations was determined by BCA protein
assay (Pierce, Rockford, IL). LDL preparations were further
characterized by measuring fluorescence at 360 nm ex/430 nm
em  (Gilford  Fluorimeter  IV,  Oberlin,  OH),  performing
agarose gel electrophoresis (Paragon® LIPO Gel, Beckman,
Fullerton, CA), and measuring absorbance at 234 nm using a
Beckman DU 650 spectrophotometer. LDL preparations were
stored in the dark under nitrogen at 4 °C in the presence of
270 μM EDTA, and were used within six weeks. Experiments
were repeated using different human samples for each pooled
LDL preparation.
Apoptosis:  time-dependent  and  dose-dependent
responses: HRCP were grown to 90% confluence in T25
flasks  (Cellstar®,  Greiner  Bio-One,  Frickenhausen,
Germany), then rendered quiescent by 24 h exposure to SFM.
HRCP were then treated with SFM, 200 mg/l N-LDL, or 5–
200 mg/l of HOG-LDL at 37 °C for 12 h. A combination of
N-LDL  and  100  or  200  mg/l  HOG-LDL  for  12  h  was
administered to investigate whether N-LDL protects HRCP
from the toxic effects of HOG-LDL. Cells were harvested
using trypsin, washed with PBS (8 g NaCl, 2 g KCl, 2.16 g
Na2HPO4, 7 g H2O, 0.208 g KH2PO4 per liter, MilliQ water,
pH  7.36–7.44),  and  incubated  with  Annexin  V-FITC  and
propidium iodide (PI) for 10 min The apoptotic signals were
determined  using  an  ExCalibur  Flow  Cytometer  (Becton
Dickinson, San Jose, CA). For fold difference calculations,
percent apoptotic values were normalized against the control
treatment.
MAPK time-response and dose–response assays: Cells
were grown to 90% confluence in 6 well tissue culture plates
(Costar®,  Corning,  NY)  or  60  mm  tissue  culture  dishes
(Becton Dickinson, Franklin Lakes, NJ) and were rendered
quiescent by 24 h exposure to SFM. For the time-response
assays, the cells were exposed to either 100 mg/l N-LDL or
100 mg/l HOG-LDL in SFM from 1 to 60 min. For the dose–
response assays, the cells were exposed to 1–100 mg/l N-LDL
or  HOG-  LDL  for  5  min.  Cells  were  harvested  for
measurement of MAPK protein by western blot.
Western blotting: Cell layers were washed three times
with ice-cold PBS, and then exposed to a detergent buffer,
which consisted of 1%Triton X-100, 0.5% Tween-20, 0.5 M
NaCl,  and  50  mM  Hepes,  pH  7.5,  and  also  contained  a
protease inhibitor mixture (EDTA-free; Roche, Mannheim,
Germany). Cells were scraped from the dish with a rubber
policeman  and  lysed  with  a  28  gauge  needle.  Protein
concentrations in extracts were determined by BCA protein
assay. Equal amounts of protein (15 μg) were separated on
Novex® pre-cast gels, which contained Tris-glycine, 4%–
20%  polyacrylamide  gradient  (Invitrogen,  Carlsbad,  CA),
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136under  reducing  conditions,  then  transferred  to  fluoride
membranes  (Pall,  Ann  Arbor,  MI).  The  membranes  were
blocked in 5% nonfat dry milk in Tris-buffered saline (TBS),
which contained 50 mM Tris, and 150 mM NaCl, pH 7.4. The
blocked  membranes  were  immunoblotted  with  a  1:1,000
dilution rabbit polyclonal tyrosine phospho-specific ERK1/2,
p38  MAPK,  or  SAPK/JNK  antibodies  (Cell  Signaling
Technology, Beverly, MA), diluted in TBS containing 5% dry
nonfat dry milk (for ERK1/2) or 5% BSA (for p38 and SAPK/
JNK) and 0.1% Tween-20, overnight at 4 °C. Membranes
were then washed with TBS 0.1% Tween-20. Total MAPK
was  measured  in  the  same  membranes  by  stripping  the
membranes with 100 mM glycine, pH 2.3, for 5 min and
immunoblotting with a 1:1,000 dilution total ERK1/2, p38
MAPK,  and  SAPK/JNK  antibodies  (Cell  Signaling
Technology).  The  membranes  were  incubated  with  a
secondary  antibody  conjugated  to  horseradish  peroxidase
(Amersham, Piscataway, NJ). Immunoreactive bands were
visualized using the chemiluminescence reagent ECL plus™
(Amersham  Pharmacia,  Piscataway,  NJ).  The  bands  for
phosphorylated  and  total  forms  were  detected  at  sites
corresponding  to  known  molecular  weights  in  all
immunoblots. Each band for P-ERK, P-p38, or P-JNK was
quantified by densitometry and normalized to T-ERK, T-p38,
or T-JNK level using the Scion Image program (Frederick,
MD).  After  this  analysis,  for  purposes  of  presentation  in
Figures, the blot images were truncated to remove portions of
lanes that were devoid of signal.
Apoptosis  in  the  presence  of  MAPK  inhibitors:  To
determine  effects  of  MAPK  inhibitors  on  apoptosis  and
cytotoxicity, we preinubated cells with each of the following
inhibitors for 1 h: 10 µM U0126 (ERK inhibitor), 10 µM
SB203580  (p38  inhibitor),  and  10  µM  SP600125  (JNK
inhibitor). LDL was then added to the medium, and cells were
incubated for a further 1 h. Medium was changed to SFM,
cells were incubated for a further 12 h, then harvested. This
modification of the aforementioned protocol (cells were only
exposed to LDL for 1 h) still yielded statistically significant
differences between 200 mg/l N-LDL and 200 mg/l HOG-
LDL without risking the degradation of the inhibitors that
might have occurred over the 12 h period.
Statistical analysis: Results were expressed as mean±SD,
and statistical significance was assessed by paired two-tailed
Student’s  t-test.  Squares  regression  was  used  to  test  dose
dependence. The level of significance was set at p<0.05.
RESULTS
LDL-induced  apoptosis:  HRCP  exposed  to  HOG-LDL
(200 mg/l) for 12 h showed a 2- to 3-fold increase in apoptosis
versus either SFM or N-LDL (200 mg/l). HRCP exposed to
N-LDL (200 mg/l) for 12 h showed no increase in apoptosis
versus SFM (Figure 1). A combination of N-LDL and HOG-
LDL did not mitigate the increased apoptosis induced by
HOG-LDL alone (Figure 1). Cells incubated for 12 h with 0,
5, 10, 25, 50, 100, and 200 mg/l of HOG-LDL showed a dose-
dependent  apoptotic  response,  maximal  at  50  mg/l  and
constant at the higher doses (Figure 2). At all doses, except
10 mg/l, the increase in apoptotic rate induced by HOG-LDL
versus SFM was significant (Figure 2).
ERK activation:
N-LDL  and  HOG-LDL  induced  ERK1/2
phosphorylation in a time-dependent manner—Quiescent
HRCP were incubated with 100 mg/l N-LDL or HOG-LDL
Figure 1. HOG-LDL induces apoptosis in HRCP. After 12 h, 200
mg/l highly oxidized-glycated low density lipoprotein (HOG-LDL)
caused a 2–3 fold increase in apoptosis (measured by Annexin V
FITC and propidium iodide) compared to serum-free medium (SFM)
and native-low density lipoprotein (N-LDL). A combination of N-
LDL and HOG-LDL did not inhibit HOG-LDL-induced apoptosis.
Bars represent mean±SD of three separate experiments. The asterisk
indicates p<0.05 compared to SFM.
Figure  2.  Effects  of  HOG-LDL  on  apoptosis  of  human  retinal
capillary pericytes. Highly oxidized-glycated low density lipoprotein
(HOG-LDL) at all doses, except 10 mg/l, significantly increased
apoptotic rate compared to serum-free medium (SFM). The asterisk
indicates p<0.05 compared to SFM; n=3. Squares regression also
showed a dose-dependent effect of HOG-LDL (below 50 mg/l) on
survival of human retinal capillary pericytes.
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137for 1, 5, 15, 30, and 60 min. For each LDL preparation,
ERK1/2 phosphorylation increased at 1 min, peaked at 5 min,
and then declined. N-LDL and HOG-LDL induced similar
increases in ERK1/2 phosphorylation (Figure 3A).
Dose-dependent  ERK  response  at  lower
concentrations  of  N-LDL  and  HOG-LDL—Quiescent
HRCP were incubated for 5 min with 1, 5, 10, 25, and 100 mg/
l of N-LDL and HOG-LDL. The two preparations induced
similar increases of ERK1/2 phosphorylation and exhibited
similar dose-dependent curves (Figure 3B).
Effect of ERK inhibition on apoptosis—U0126 was
employed as an inhibitor of ERK. U0126 (10 µM) did not
inhibit apoptosis induced by HOG-LDL at 100 mg/l (data not
shown) or at 200 mg/l (Figure 4).
p38 MAPK activation:
N-LDL  and  HOG-LDL  induced  p38  MAPK
phosphorylation in a time-dependent manner—Quiescent
HRCP were incubated with 100 mg/l of N-LDL and HOG-
LDL for 1, 5, 15, 30, and 60 min. For each LDL preparation,
p38 MAPK phosphorylation increased at 1 min, peaked at 5
Figure  4.  Effects  of  U0126  on  HOG-LDL-induced  apoptosis.
Administration of 10 µM U0126, an inhibitor of extracellular signal-
regulated  kinase  (ERK)  signaling  pathways,  did  not  decrease
apoptosis  induced  by  at  200  mg/l  highly  oxidized-glycated  low
density lipoprotein (HOG-LDL). Bars represent mean±SD of three
separate experiments. The asterisk indicates p<0.05 compared to
serum-free medium (SFM).
Figure 3. LDL increases ERK phosphorylation.  A:  This panel shows representative western immunoblots from one experiment, and
densitometric data from three experiments (mean±SD) describing the time course of LDL-induced ERK phosphorylation (P-ERK and T-ERK
means phosphorylated and total ERK). B: This panel shows representative western immunoblots from one experiment, and densitometric data
from three experiments (mean±SD) describing dose effects of LDL on ERK phosphorylation. N-LDL and HOG-LDL had similar effects on
ERK1/2 phosphorylation. Control immunosignal (T-ERK) bands were detected in the same gels as P-ERK after stripping and re-probing. In
both panels, densitometric calculations of P-ERK were corrected for T-ERK. Asterisk represents p<0.05 compared to control (Time 0 or Dose
0).
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138min, and then declined (Figure 5A). Responses to N-LDL and
HOG-LDL were similar.
Dose-dependent  p38  MAPK  responses  at  lower
concentrations  of  N-LDL  and  HOG-LDL—Quiescent
HRCP were incubated for 5 min with 1, 5, 10, 25, and 100 mg/
l of N-LDL and HOG-LDL. N-LDL and HOG-LDL showed
similar effects on p38 MAPK phosphorylation, with similar
dose–response curves (Figure 5B).
Effect of p38 inhibition on apoptosis—SB203580 was
employed as an inhibitor of p38 MAPK. SB203580 (10 µM)
did not inhibit apoptosis induced by HOG-LDL at 100 mg/l
(data not shown) or at 200 mg/l (Figure 6).
JNK activation:
Phosphorylation of JNK by native and modified LDL
—Quiescent HRCP were incubated with 100 mg/l of N-LDL
and  HOG-LDL  for  1,  5,  15,  30,  and  60  min.  JNK  p46
phosphorylation was increased at 1 min, peaked at 5 min, and
then declined. JNK p54 phosphorylation peaked at 15 min
(Figure 7A). N-LDL and HOG-LDL showed similar effects
on JNK phosphorylation.
Dose-dependent  JNK  response  at  lower
concentrations  of  N-LDL  and  HOG-LDL—Quiescent
HRCP were incubated for 5 min with 1, 5, 10, 25, and 100 mg/
l  of  N-LDL,  and  HOG-LDL.  N-LDL  and  HOG-LDL
exhibited  similar  dose-dependent  response  curves  for
phosphorylation of JNK (Figure 7B).
Effect of JNK inhibition on apoptosis—SP600125 was
employed as an inhibitor of JNK. SP600125 (10 µM) did not
inhibit apoptosis induced by HOG-LDL at 100 mg/l (data not
shown) or at 200 mg/l (Figure 8).
To block MAPK signaling pathways, we used specific
inhibitors U0126 (ERK), SB203580 (p38), and SP600125
(JNK) [24-26]. None inhibited apoptosis triggered by HOG-
LDL. At 10 μM, each inhibitor is known to block activation
of its target enzyme [27-29]. In separate experiments, we
confirmed  their  efficacy:  HRCP  were  pre-incubated  with
10 μM of each inhibitor for 1 h, then co-exposed to inhibitors
and HOG-LDL for 30 or 60 min, and significant reductions in
pathway activity were observed (data not shown).
DISCUSSION
Retinal capillary pericyte loss by apoptosis is an established
early  feature  of  DR.  Pericytes  are  numerous  in  retinal
capillaries compared to other capillary beds. They regulate
endothelial cell proliferation and survival, and maintain the
integrity of retinal capillaries. In DR, they undergo apoptosis
that  results  in  so-called  “pericyte  ghosts.”  Dyslipidemia,
defined  as  qualitative  and  quantitative  abnormalities  of
plasma lipoproteins, is associated with the severity of DR
Figure 5. LDL increases p38MAPK phosphorylation. A: This panel shows representative western immunoblots from one experiment, and
densitometric data from three experiments (mean±SD) describing the time course of LDL-induced p38 MAPK phosphorylation (P-p38MAPK
and T-p38MAPK means phosphorylated and total p38 MAPK). B: This panel shows representative western immunoblots from one experiment,
and densitometric data from three experiments (mean±SD) describing dose effects of LDL on p38 MAPK phosphorylation. N-LDL and HOG-
LDL had similar effects on p38 MAPK phosphorylation. Control immunosignal (T-p38MAPK) bands were detected in the same gels as P-
p38MAPK after stripping and re-probing. In both panels, densitometric calculations of P-p38MAPK were corrected for T-p38MAPK. Asterisk
represents p<0.05 compared to control (Time 0 or Dose 0).
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139based  on  accumulating  evidence  from  clinical  studies
including  the  Diabetes  Control  and  Complications  Trial/
Epidemiology of Diabetes Intervention and Complications
(DCCT/EDIC),  Hoorn,  and  Pittsburgh  Epidemiology  of
Diabetic  Complications  studies  [30-32].  For  example,  we
found  associations  between  DR  and  adverse  plasma
lipoprotein  subclass  distributions,  especially  in  men  [31].
Retinal hard exudates regress significantly after correction of
dyslipidemia [33,34]. However, we hypothesize that the most
important effects of plasma lipoproteins in the promotion of
DR occur after they are extravasated through a damaged blood
retinal barrier, become modified, and mediate injury to cells
in their vicinity.
Oxidation of LDL in the subintimal space of arterial walls
is  now  accepted  as  a  potent  stimulus  for  atherogenesis
[35-37]. In the present and related work, we hypothesize that
an analogous process is implicated in DR [14,15,17,18]. This
notion is strengthened by the demonstration of extravasated
LDL, using immunohistochemistry, in wet macular edema
[33], and by ourselves in human retinal samples from diabetic
and  normal  controls  [16].  Our  studies  demonstrated  the
presence of oxidized and aggregated LDL in human retina in
diabetics in proportion to the severity of DR [16]. In contrast,
oxidized LDL is absent in the absence of diabetes. These
findings are consistent with potential roles of modified LDL
in the initiation and development of DR. Furthermore, we
have shown that HOG-LDL has strong cytotoxic effects on
cultured bovine retinal pericytes and endothelial cells in vitro
[14]  and  induces  the  programmed  cell  death  of  human
pericytes  [15,16].  In  the  present  study  we  investigate  the
involvement of the three MAPK subfamilies–ERK, JNK, and
p38–in apoptosis induced by HOG-LDL versus N-LDL in
HRCP.
MAPKs have been shown to be the central mediators that
propagate extracellular signal inputs from cell membrane to
the nucleus. They have been shown to play a key role in
apoptosis in different tumor cell lines [38-40] and in primary
cell cultures [41,42]. At least three structurally related MAPK
subfamilies have been identified in mammalian cells: ERK,
p38, and JNK. MAPK subfamilies are activated in response
to different extracellular stimuli, have different downstream
targets, and therefore perform different functions including
mediation  of  apoptosis,  proliferation,  angiogenesis,  and
inflammation [43-45].
It  is  generally  accepted  that  ERK  activation  plays  a
principal  role  in  cell  proliferation,  differentiation,  and
apoptosis [43,46]. In the present study, we show that N-LDL
and HOG-LDL induced a rapid phosphorylation of ERK in
retinal capillary pericytes. We demonstrate that N-LDL and
HOG-LDL showed the same time course of ERK activation,
peaking at 5 min. Our data are in general agreement with
previous studies that showed native and copper-oxidized LDL
stimulated ERK1/2 activation in other cells such as renal
mesangial cells or vascular smooth muscle cells (VSMC)
[23,47]. However, the relative effects of the different LDL
preparations  vary  among  the  various  vascular  cell  types.
HOG-LDL is a more potent activator of ERK than N-LDL in
renal  mesangial  cells  [23],  while  N-LDL  induces  a  more
potent response than HOG-LDL in VSMC [47]. In contrast to
those  studies,  N-LDL  and  HOG-LDL  induced  similar
increases  in  ERK1/2  phosphorylation  in  HRCP.  The
sensitivity of vascular cells to normal and modified LDL also
seems to vary between cell types. In renal mesangial cells, we
found dose-dependent ERK activation in doses up to 100 mg/
l. We also demonstrated that at a low dose (10 mg/l), the effect
of  N-LDL  was  greater  than  that  of  HOG-LDL  [23].  Our
findings with retinal pericytes confirm the dose-dependency
of  the  ERK  response  but  showed  that  it  occurs  at  lower
concentrations  (maximal  at  10–25  mg/l)  than  in  renal
mesangial cells (maximal at 50–100 mg/l) and to be detectable
at very low LDL concentrations (1 and 5 mg/l). This indicated
that relatively small amounts of N-LDL and modified LDL
may trigger retinal cell signaling cascades in pericytes, which
may influence retinal responses to diabetes.
It has been established that p38 MAPK can be activated
by a variety of environmental stresses such as osmotic shock,
ultraviolet  radiation,  heat  shock,  and  pro-inflammatory
cytokines, and that activation of p38 MAPK cascades can
trigger  apoptosis  [48].  Concentration-  and  time-dependent
activation  of  p38  MAPK  by  oxidized  LDL  in  rat  VSMC
(maximal at 100 mg/l within 5 min) was demonstrated by Jing
et al. [49]. In contrast, N-LDL was a much weaker activator
of this pathway. Our present data show that N-LDL and HOG-
LDL  induced  p38  MAPK  phosphorylation  in  a  time-
dependent manner in human retinal pericytes, peaking at 5
min, but the responses to the two lipoprotein preparations
were similar.
Figure 6. Effects of SB203580 on HOG-LDL-induced apoptosis.
Administration of 10 µM SB203580, an inhibitor of p38MAPK
signaling pathways, did not inhibit highly oxidized-glycated low
density lipoprotein (HOG-LDL)-induced apoptosis in human retinal
capillary  pericytes  (HRCP).  Bars  represent  mean±SD  of  three
separate experiments. The asterisk indicates p<0.05 compared to
serum-free medium (SFM).
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140The JNK family of protein kinases, also known as SAPK,
is implicated in apoptosis [50-52]. The JNK family includes
three  genes,  JNK1,  JNK2,  and  JNK3,  each  of  which  can
produce 46 kDa and 54 kDa isoforms [53,54]. Zhu et al. found
that N-LDL activated JNK in human endothelial cells, starting
at 15 min and peaking at 1–2 h [55]. In the present study,
p46JNK phosphorylation was increased at 1 min, peaked at 5
min, and then declined. p54 JNK phosphorylation peaked at
15 min. As with ERK and p38 MAPK, there was no difference
in the magnitude of responses to N-LDL and HOG-LDL.
Inhibition of each of the three MAPK pathways had no
effect in preventing apoptosis following exposure to HOG-
LDL. All of our data therefore suggest that these MAPK
pathways do not play a significant role in HOG-LDL-induced
apoptosis in HRCP, and that the responses in these cells differ
both qualitatively and quantitatively from those studied from
the kidney (renal mesangial cells) and arterial wall (VSMC).
Although HOG-LDL-induced apoptosis did not depend on
altered  MAPK  pathway  activation,  several  studies  have
suggested  that  MAPK  pathways  are  implicated  in
pathogenesis  of  DR.  MAPK  pathways  are  recognized  as
mediators of cellular responses to elevated glucose levels, and
hence as mediators of the development of the complications
of diabetes, including DR [56]. MAPK has been shown to
respond to several forms of cellular stress that are present in
DR  and  to  be  associated  with  biochemical  abnormalities
relevant to the progression of DR [57,58]. Examples are as
follows: prevention and reversal of diabetic retinal vascular
changes by angiopoietin-1 was attributed in part to decreased
MAPK activity [59]; inhibition of endothelial cell growth by
PEDF  may  result  from  inhibition  of  vascular  endothelial
growth factor (VEGF)-induced MAPK activation [60]; and
inhibition of VEGF-induced angiogenesis by the hepatocyte
growth factor/NK4 depends on inhibition of ERK activation
in both in vitro and in vivo models [61]. Therefore inhibitors
of MAPK pathways may have potential uses in attenuating
VEGF-induced angiogenesis and revascularization [62].
Figure  7.  LDL  increases  JNK  phosphorylation.  A:  This  panel  shows  representative  western  immunoblots  from  one  experiment,  and
densitometric data from three experiments (mean±SD) describing the time course of LDL-induced phosphorylation of the two isoforms of
JNK, p54, and p46 (P-JNK and T-JNK means phosphorylated and total JNK). B: This panel shows representative western immunoblots from
one  experiment,  and  densitometric  data  from  three  experiments  (mean±SD)  describing  dose  effects  of  LDL  on  p54  and  p46  JNK
phosphorylation. N-LDL and HOG-LDL had similar effects on phosphorylation of both JNK isoforms. Control immunosignal (T-JNK) bands
(both isoforms) were detected in the same gels as P-JNK after stripping and re-probing. In both panels, densitometric calculations of P-JNK
were corrected for T-JNK. Asterisk represents p<0.05 compared to control (Time 0 or Dose 0).
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141Besides apoptosis, MAPK signaling pathways mediate
inflammation (e.g., by stimulating arachidonic acid synthesis
[44]), angiogenesis by promoting formation of capillary-like
structures in co-cultured human umbilical vein endothelial
cells and fibroblasts [45], and atherosclerosis by activating
scavenger  receptors,  vascular  smooth  muscle  proliferation
and forming foam cells [47,63,64]. Furthermore, our previous
studies showed that when cells are exposed to HRCP to HOG-
LDL, then compared to cells exposed to N-LDL or SFM, there
is an alteration in specific genes including several implicated
in  fatty  acid  and  eicosanoid  metabolism,  fibrinolytic
regulation,  tissue  inhibition  of  metalloproteinases,  and
angiogenesis  [15,18].  Therefore,  activation  of  MAPK
signaling pathways by HOG-LDL and N-LDL in HRCP might
be  implicated  in  other  pathways  of  retinal  injury,  e.g.,
involving inflammation [44] and angiogenesis [65,66]. Future
studies  are  necessary  to  elucidate  these  potential  roles  of
HOG-LDL and the different effects of N-LDL and HOG-LDL
in  DR.  It  must  be  borne  in  mind  that  under  normal
circumstances, neither version of the lipoprotein leaks into the
retinal extravascular space. Another direction for future work
is to determine molecular signaling pathways stimulated by
multiple  exposures  of  HOG-LDL,  which  might  mimic
repetitive stresses under biologic conditions.
With regard to potential alternative mechanisms by which
HOG-LDL  elicits  apoptosis  in  retinal  pericytes,  we  have
demonstrated  that  HOG-LDL  increased  Bax  protein  level
[16], a well known marker for mitochondrial dysfunction.
Further, caspases 3 and 7 were activated after 24 h incubation
of  HRCP  with  HOG-LDL  [16].  Activation  of
cyclooxygenase-2 pathways and enhanced oxidative stress are
also implicated in pericyte loss triggered by HOG-LDL [67].
The  LDL  concentration  range  was  chosen  as
representative of LDL concentrations that pericytes may be
Figure 8. Effects of SP600125 on HOG-LDL-induced apoptosis.
Administration of 10 µM SP600125, an inhibitor of Jun N-terminal
kinase (JNK) signaling pathways, did not block apoptosis in human
retinal  capillary  pericytes  (HRCP)  induced  by  highly  oxidized-
glycated low density lipoprotein (HOG-LDL). Bars represent mean
±SD of three separate experiments. The asterisk represents p<0.05
compared to serum-free medium (SFM).
exposed to in vivo in diabetes. For example, a concentration
of 100 mg/l of LDL protein corresponds to 10 to 20% of the
normal circulating level of LDL. It is estimated that between
5  to  25%  of  circulating  LDL  may  be  non-enzymatically
modified in vivo in diabetes [18].
In summary, we report that HOG-LDL induced apoptosis
in cultured HRCP in a time- and dose-dependent manner. All
three  MAPK  component  pathways  in  retinal  capillary
pericytes were activated by both native and modified LDL, all
in a time- and dose-responsive manner. However, responses
to  N-LDL  and  HOG-LDL  were  similar,  and  blockade  of
individual pathways for ERK, p38, and JNK did not prevent
HOG-LDL-induced apoptosis. Therefore, although they may
mediate other responses of pericytes in DR, MAPK pathways
do not appear to be directly involved in the induction of
apoptosis in these cells.
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